I often write about fatty liver disease, a problem that is gaining mainstream recognition as published earlier this year in Newsweek. It is easy to assume that this is a...
Read More
By Peter G. Traber, M.D. on October 21, 2015 Bristol-Myers Squibb ($BMS) recently paid $150 million for the exclusive right to acquire Promedior, a clinical-stage biotechnology company in the midst...
Read More
Written by Peter G. Traber, M.D. on October 8, 2015 On September 14, 2015, Raptor Pharmaceutical Corp. (NASDAQ: RPTP) announced top-line results of its Phase 2b trial evaluating RP103 in...
Read More
Written by Peter G. Traber, M.D. on September 2, 2015 In late June 2015, Galectin Therapeutics initiated a Phase 2 clinical trial (the NASH-CX trial) to evaluate the ability of...
Read More